Skip to main content
OpenTrials
Recruiting

NCT Number: NCT04970888

Comparing the Effects of Combining Cognitive and Physical Exercise Training on Cognition, and Cerebral Blood Flow Regulation in Men and Women With Chronic Heart Failure

The objective of this project is to assess the effects of combined physical exercise and cognitive training interventions on cognitive and brain health in patients with heart failure (HF). Also, the role of sex on the effects of the interventions will be assessed.

Recruiting

Interested in participating?

Request Info

Key information

Age range

50 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Preventive medicine and physical activity centre (centre EPIC), Montreal Heart Institute

Montreal, Quebec, H1T1N6, Canada

Location status: Recruiting

Location contact

Anil Nigam, MD

SUB_INVESTIGATOR

Jean Rouleau, MD

SUB_INVESTIGATOR

Louis Bherer, PhD

CONTACT

[email protected]

514-374-1480 ext. 4355

Louis Bherer, PhD

PRINCIPAL_INVESTIGATOR

About this study

Cognitive impairment (CI) affects up to 50% of patients with heart failure (HF), and is associated with high mortality rates, poor quality of life, reduced functional capacities, and an overwhelming economic burden in Western countries. Non-pharmacological strategies could help enhance cognition in HF patients with CI. Combined physical exercise and cognitive training interventions have recently shown promising enhancement effects on cognition in patients with cardiovascular risk factors and mild cognitive impairment. The effects of combined interventions have never been tested in HF.

The main objective is to assess the effects of combined physical exercise and cognitive training interventions on cognition in patients with HF. Secondary objectives include: to characterize baseline and intervention-related changes in cerebral autoregulation, pulsatility and neurovascular coupling and to assess the role of sex on intervention effects.

Two-hundred and sixteen participants (36 men and 36 women/group) with stable HF regardless of aetiology and LVEF will take part in this study. All participants will have signed a written consent form before taking part in the study.

Patients will be stratified according to sex and LVEF (FEVG < 40% et FEVG > 40%), and will be randomly assigned to one of the 3 following study arms: 1) Combined physical exercise and cognitive training; 2) Physical exercise alone; and 3) Usual medical care.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥ 50 years old
  • Stable chronic HF on maximally tolerated background treatment for at least 2 months (stable therapy with ACE-I, ARBs and MRA for at least 2 months), regardless of LVEF
  • with no limitation of physical activity in ordinary physical activity (i.e. NYHA class I), moderate symptoms (i.e. NYHA class II) or marked limitation in activity (i.e. NYHA class III)
  • Able to perform cognitive and physical training.

Exclusion criteria

  • Acute cardiovascular event 1 month prior to randomization, including emergency visit or hospitalization for decompensated HF, acute myocardial infarction, stroke, and transient ischemic attack
  • Planned cardiovascular intervention within 6 months (implantation of any cardiac device, cardiac revascularization, heart transplantation)
  • Severe exercise intolerance
  • Contraindications for exercise testing (e.g., uncorrected severe aortic or carotid stenosis, severe pulmonary hypertension, severe non-revascularizable coronary disease including left main coronary stenosis, significant myocardial ischemia or arrhythmia during low-intensity exercise, acute HF)
  • Severe respiratory disease
  • Non-cardiopulmonary limitation to exercise (e.g., arthritis, claudication or any peripheral neurological disease including other neurodegenerative diseases such as disabling Parkinson)
  • Uncontrolled diabetes or untreated thyroid dysfunction
  • Current or recent malignancy with life expectancy < 1 year
  • Chronic hemodialysis or peritoneal dialysis
  • Unable to read the informed consent form or unable to understand the oral explanations provided by the assessor.

Treatment and study plan

Cognitive Training

Other

The cognitive training will involve attention control training and memory training, with thrice-weekly 30-min sessions.

Two of these sessions will involve computer or tablet-based attentional control training targeting dual-tasking, updating and working memory, as well as inhibition and switching. Difficulty of cognitive training will be tailored to participants' performances. The remaining session will consist of memory training. Participants will be instructed mnemotechnic, as well as be taught about memory in aging in general.

Exercise training

Other

Participants will follow a 20-week physical training program, with 60-min thrice-weekly trainings. The training sessions will start with a 5-min warm-up, followed by an aerobic training (20 min) after which 20-min of resistance/muscular training will take place. The program will end with a 10-min cool-down. Training will be adapted to individuals' baseline capacity as measured by the baseline cardiorespiratory test. For home-training sessions, participants will have access to a complete exercise training program. A certified kinesiologist will supervise trainings. With the Heart rate sensor Polar H10, all the characteristics of the activities will be recorded (type of the activity, intensity, heart rate, duration). A kinesiologist will call participants every week to ensure the smooth running of the exercises training sessions and individualize the care according to the patient's level.

Usual Care

Other

All patients will receive usual care and be treated according to evidence-based treatments. This will include optimal medical therapy, systematic information regarding dietary and fluid management, and a recommendation for regular physical activity consistent with the latest update of the Canadian Cardiovascular Society Guidelines for the Management of Heart Failure. Moreover, patients who benefit from a prescription for a cardiovascular rehabilitation program will be able to follow it, but they will not receive other forms of intervention for the duration of the study.

Primary outcomes

  1. Change in general cognitive functioning

    Time frame: Baseline and post-intervention at 6 months

    Montreal Cognitive Assessment (0-30 score, with a higher score indicating a better cognitive functioning).

  2. Change in processing speed

    Time frame: Baseline and post-intervention at 6 months

    Validated remote version of neuropsychological tests and iPad tests (Composite Z-score).

  3. Change in executive functions

    Time frame: Baseline and post-intervention at 6 months

    Validated remote version of neuropsychological tests and iPad tests (Composite Z-score).

  4. Change in episodic memory

    Time frame: Baseline and post-intervention at 6 months

    Validated remote version of neuropsychological tests (Composite Z-score).

Secondary outcomes

  1. Change in cerebral autoregulation - frontal cortical region

    Time frame: Baseline and post-intervention at 6 months

    Variations of prefrontal cortical oxygen saturation (rSO2, [HbO]/([HbO]+[HbR])) will be measured by Near Infrared Spectroscopy (NIRS), as a surrogate of cortical blood flow. Variations of continuous peripheral blood pressure (mm Hg) will be simultaneously measured by plethysmography at the finger. Autoregulation indices (unitless) will be derived from the correlation between variations of oxygen saturation measures and variations of peripheral blood pressure.

  2. Change in cerebral autoregulation - middle cerebral arteries

    Time frame: Baseline and post-intervention at 6 months

    Variations of cerebral blood flow velocity (cm/s) at the level of the middle cerebral artery will be measured by Transcranial Doppler (TCD). Variations of continuous peripheral blood pressure (mm Hg) will be simultaneously measured by plethysmography at the finger. Autoregulation indices (unitless) will be derived from the correlation between variations of cerebral blood flow measures and variations of peripheral blood pressure.

  3. Change in cerebral pulsatility - cortical frontal region

    Time frame: Baseline and post-intervention at 6 months

    Pulsatility will be measured as the normalized difference of relative near-infrared light intensity changes between systole and diastole, using NIRS in the prefrontal cortical region.

  4. Change in cerebral pulsatility - middle cerebral arteries

    Time frame: Baseline and post-intervention at 6 months

    Pulsatility will be measured as the normalized difference of relative blood flow velocities between systole and diastole, using TCD in the middle cerebral arteries

  5. Change in cerebral activity

    Time frame: Baseline and post-intervention at 6 months

    Significant changes in brain activity evoked by a Stroop task relative to baseline will be assessed by t-statistics maps, computed from variations of [HbO] and [HbR] measured by NIRS at the prefrontal cortex.

Other outcomes

  1. Change in cardiorespiratory fitness

    Time frame: Baseline and post-intervention at 6 months

    Maximum incremental cardiopulmonary exercise test (VO2 max (ml.kg.min)

  2. Change in 6-min walking test performance

    Time frame: Baseline and post-intervention at 6 months

    maximum distance performed in 6 minutes (distance, m)

  3. Change in upper limb muscle strength

    Time frame: Baseline and post-intervention at 6 months

    Grip strength test score (kg).

  4. Change in quality of life

    Time frame: Baseline and post-intervention at 6 months

    score on the 23 items of the Kansas City Cardiomyopathy Questionnaire (KCCQ)

  5. Change in perceived self care behaviour

    Time frame: Baseline and post-intervention at 6 months

    European Heart Failure Self-care Behaviour Scale (EHFScB-9) will be completed. This self-reported questionnaire assesses the adherence to different self-care behaviours (e.g., eating low-salt diet, etc.).

  6. Change in anxiety

    Time frame: Baseline and post-intervention at 6 months

    State-Trait Anxiety Inventory questionnaire (Score ranges from 20-80, with a higher score indicating higher anxiety).

  7. Change in depressive symptoms

    Time frame: Baseline and post-intervention at 6 months

    Geriatric Depression Scale questionnaire (Score ranges from 0-30, with a higher score indicating larger depressive symptomatology).

  8. Change in sleep quality

    Time frame: Baseline and post-intervention at 6 months

    Pittsburgh Sleep Quality Index questionnaire (Score ranges from 0-21, with a higher score indicating worse sleep quality). symptomatology).

  9. Cognitive reserve

    Time frame: Baseline

    Rami and colleagues' cognitive reserve questionnaire (Scale ranges from 0-26, with a higher score indicating a greater cognitive reserve).

  10. Genotyping data

    Time frame: baseline

    genotyping data that include the APOE gene

  11. Change in NT-pro-BNP

    Time frame: Baseline and post-intervention at 6 months

    NT-pro-BNP (ng/L)

  12. Change in high-sensitive Troponin T

    Time frame: Baseline and post-intervention at 6 months

    hsTnT (ng/mL)

Study contacts

Contact information is provided by the study sponsor or research team.

Louis Bherer, PhD

CONTACT

[email protected]

+1 514-374-1480 ext. 4355

Sponsors and collaborators

Lead sponsor

Montreal Heart Institute

Other

Collaborators

  • Canadian Institutes of Health Research (CIHR)
  • The Montreal Health Innovations Coordinating Center (MHICC)

Registry information

Acronym: ReCARDIO

Important dates

Study start
2021
Primary completion
2026
Study completion
2026
First posted
Jul 21, 2021
Registry last updated
Dec 2, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.